Introduction
NSCLC, advanced/metastatic NSCLC
NON-SMALL CELL LUNG CANCER, NSCLC
Although the treatment landscape for advanced non-small cell lung cancer (NSCLC) has undergone recent advances, there remains an unmet need for well-tolerated and clinically effective treatments for patients who progress after first-line immunochemotherapy. The known interrelationship between pro-angiogenic factors and immune evasion provides a strong rationale for the use of anti-angiogenic treatments in patients with NSCLC in this setting [In the phase III registration trial, LUME-Lung 1, nintedanib (200 mg twice daily [BID]) plus docetaxel (75 mg/mThis phase I study aimed to build on the existing evidence by exploring the maximum tolerated dose (MTD) of nintedanib and its tolerability in combination with a weekly schedule of docetaxel in patients with advanced/metastatic NSCLC after failure of first-line therapy.